Prognostic value of NT-proBNP in patients with severe COVID-19

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury is a common condition among the hospitalized patients with COVID-19. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of severe COVID-19 patients was unknown.

Methods

The study initially enrolled 102 patients with severe COVID-19 from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. The primary outcome was in-hospital death defined as the case fatality rate. Research information and following-up data were obtained from their medical records.

Results

The best cut-off value of NT-proBNP for predicting in-hospital death was 88.64 pg/mL with the sensitivity for 100% and the specificity for 66.67%. Patients with high NT-proBNP values (> 88.64 pg/mL) had a significantly increased risk of death during the days of following-up compared with those with low values (≤88.64 pg/mL). After adjustment for potential risk factors, NT-proBNP was independently correlated with in-hospital death.

Conclusion

NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19.

Trial registration

ClinicalTrials, NCT04292964. Registered 03 March 2020,

Related collections

Most cited references 14

Record: found
Abstract: found
Article: not found

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang, Yeming Wang, Xingwang Li … (2020)

Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.

0 comments Cited 21786 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate

Elisabeth Mahase (2020)

0 comments Cited 298 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Is COVID-19 receiving ADE from other coronaviruses?

Jason Tetro (2020)

One of the most perplexing questions regarding the current COVID-19 coronavirus epidemic is the discrepancy between the severity of cases observed in the Hubei province of China and those occurring elsewhere in the world. One possible answer is antibody dependent enhancement (ADE) of SARS-CoV-2 due to prior exposure to other coronaviruses. ADE modulates the immune response and can elicit sustained inflammation, lymphopenia, and/or cytokine storm, one or all of which have been documented in severe cases and deaths. ADE also requires prior exposure to similar antigenic epitopes, presumably circulating in local viruses, making it a possible explanation for the observed geographic limitation of severe cases and deaths.

0 comments Cited 215 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Guo-qiang Cai: 185161439@qq.com

Dong-ying Zhang: zhangdongying@cqmu.edu.com

Journal

Journal ID (nlm-ta): Respir Res

Journal ID (iso-abbrev): Respir. Res

Title: Respiratory Research

Publisher: BioMed Central (London )

ISSN (Print): 1465-9921

ISSN (Electronic): 1465-993X

Publication date (Electronic): 15 April 2020

Publication date PMC-release: 15 April 2020

Publication date (Print): 2020

Volume: 21

Electronic Location Identifier: 83

Affiliations

[1 ]GRID grid.452206.7, Department of Cardiovascular Medicine, , The First Affiliated Hospital of Chongqing Medical University, ; Chongqing, 400016 China

[2 ]GRID grid.452206.7, Department of Cardiovascular Medicine, , The First Branch of the First Affiliated Hospital of Chongqing Medical University, ; Chongqing, 400016 China

[3 ]Traditional Chinese Medicine hospital Dianjiang Chongqing, Chongqing, 408300 China

Article

Publisher ID: 1352

DOI: 10.1186/s12931-020-01352-w

PMC ID: 7156898

PubMed ID: 32293449

SO-VID: 462da49c-bc94-498b-9bed-9cd6551a05f9

License:

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

History

Date received : 11 March 2020

Date accepted : 2 April 2020

Funding

Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;

Award ID: 81570212

Award ID: 31800976

Funded by: Chongqing Science and Health Joint Medical Research Project

Award ID: 2018QNXM024

Custom metadata

ScienceOpen disciplines: Respiratory medicine

Keywords: nt-probnt,covid-19,sars-cov-2,outcome

Data availability:

ScienceOpen disciplines: Respiratory medicine

Keywords: nt-probnt, covid-19, sars-cov-2, outcome

Comments

Comment on this article

scite_

Cited by 132

See all cited by

Most referenced authors 1,385

See all reference authors

- Version 1

Prognostic value of NT-proBNP in patients with severe COVID-19

Read this article at

Abstract

Background

Methods

Results

Conclusion

Trial registration

Related collections

Novel Coronavirus Disease COVID-19

Most cited references 14

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate

Is COVID-19 receiving ADE from other coronaviruses?

Author and article information

Contributors

Journal

Affiliations

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 1,283

Cited by 132

Most referenced authors 1,385